Novonesis and CHR. Hansen completed the merger, and Novonesis was officially established

On January 29, 2024, the proposed merger of the long-established companies Novonesis and CHR. Hansen was officially completed, which also announced the formation of Novonesis. Novonesis is committed to being a leading global partner for biological solutions that drive better business, healthier lifestyles and a more sustainable planet. The combined company brings together more than 10,000 employees worldwide with expertise across more than 30 different industry sectors.

On December 12, 2022, Novonesis and CHR Hansen reached an agreement to create a leading global biological solutions partner through the statutory merger of the two companies. Today, following the completion of the final registration with the Danish Business Administration, all regulatory approvals and registration procedures are in place and the proposed merger is officially completed.

″Ester Baiget, President and CEO of Novonesis, said: "We have finally completed the merger of Novonesis and CHR Hansen, and from today, together we will become the world's leading biological solutions partner. By combining our common strengths with the mysteries of biology, Novonesis will usher in a new era of biological solutions. We will continue to innovate and develop transformative biological solutions to improve human production, consumption and lifestyle."

″Cees de Jong, Chairman of Novonesis, said: "I am delighted to witness the combination of Novonesis and CHR Hansen, joining forces to create a truly global leader in biological solutions. We will build on more than 100 years of expertise in innovation and application to continue to deliver robust biological solutions to our customers and partners. Together, we will be a growth partner for our customers, a value creator for our shareholders, and a company that has a significant, positive impact on society and the planet. Novonesis is built on a tradition of sustainability leadership and will continue to be a leader."

The combination of Novonesis and CHR Hansen will create a leading global biosolutions partner with a rich portfolio of biosolutions and a diversified product portfolio in the market. The combined group has annual revenues of approximately €3.7 billion with solid profitability and good cash flow.The combined group will operate a global network of research and development, application centers and manufacturing sites. Half of the new company's portfolio will focus on enabling healthier lives and producing better food, while the other half will focus on reducing chemical use and achieving climate neutrality. The future revenue report will be divided into two sections, each of which will provide performance in the following sales areas: 

Biological solutions for Food and Health include:

Food and Beverage (Novonesis' Food and Beverage Business and CHR Hansen's Food Strains and Enzymes business)
 

Human Health (Novonesis' Human Health Business and CHR Hansen's Human Health business)
 

Biosolutions for Planet health include:

Agriculture, Energy and Technology Industries (Novonesis' Bioenergy, Agriculture and Animal Health/Nutrition, Grains and Technical Processing businesses and CHR Hansen's Animal and Plant Health businesses)
 

Home Care (Novonesis' Home Care business)
 

The official Chinese name of Novonesis will be announced in the near future.